Skip to main content

Advertisement

SpringerLink
Log in

Evaluation of maternal serum sestrin-2 levels in intrauterine growth restriction

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Sestrin-2 (SESN2) is a antioxidant protein that can be activated by a number of conditions, including DNA damage and hypoxia.

Aims

Our objective was to evaluate maternal serum SESN2 levels in patients with intrauterine growth restriction (IUGR) and its association with adverse perinatal outcomes.

Methods

This prospective study included a total of 87 pregnant women admitted to our tertiary care center between 2018 August and 2019 July. The study group consisted of a total of 44 patients who had been diagnosed with IUGR. Forty-three low-risk and gestational age-matched pregnant women were taken as control group. Demographic data, maternal serum SESN2 levels, and maternal-neonatal outcomes were evaluated. SESN2 levels were analyzed by the enzyme-linked immunosorbent assay (ELISA) method and compared between groups.

Results

Maternal serum SESN2 levels were significantly higher in the IUGR group compared to control group (22.38 ng/ml vs. 13.0 ng/ml, p < 0.001). In correlation analysis, a negative significant correlation was found between SESN2 levels and gestational week at delivery (r = − 0.387, p < 0.001). The ideal cut-off value for detecting IUGR was 9.5 ng/ml, and the area under the curve was 0.719 (95%CI: 0.610–0.827). Birth interval, gestational week at birth, birth weight, and 1–5-min Apgar scores were lower in the IUGR group (p < 0.001).

Conclusions

Maternal serum SESN2 levels are elevated in IUGR and are associated with adverse neonatal outcome. Considering that SESN2 is involved in pathogenesis, it can be used as a new marker for the evaluation of IUGR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Obstetrics and the Society forMaternal-FetalMedicin (2019) ACOG Practice Bulletin No. 204: fetal growth restriction. Obstet Gynecol 133:e97–e109

    Article  Google Scholar 

  2. Burton GJ, Redman CW, Roberts JM, Moffett A (2019) Pre-eclampsia: pathophysiology and clinical implications. BMJ 366:l2381

    Article  PubMed  Google Scholar 

  3. Chen HL, Yang YP, Hu XL et al (1991) Tumor necrosis factor alpha mRNA and protein are present in human placental and uterine cells at early and late stages of gestation. Am J Pathol 139:327–335

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Baack ML, Wang C, Hu S et al (2014) Hyperglycemia induces embryopathy, even in the absence of systemic maternal diabetes: an in vivo test of the fuel mediated teratogenesis hypothesis. Reprod Toxicol 46:129–136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kameda T, Matsuzaki N, Sawai K et al (1990) Production of interleukin-6 by normal human trophoblast. Placenta 11:205–213

    Article  CAS  PubMed  Google Scholar 

  6. Benyo DF, Miles TM, Conrad KP (1997) Hypoxia stimulates cytokine production by villous explants from the human placenta. J Clin Endocrinol Metab 82:1582–1588

    CAS  PubMed  Google Scholar 

  7. Buckbinder L, Talbott R, Seizinger BR, Kley N (1994) Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Proc Natl Acad Sci U S A 91:10640–10644

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Velasco-Miguel S, Buckbinder L, Jean P et al (1999) PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18:127–137

    Article  CAS  PubMed  Google Scholar 

  9. Budanov AV, Shoshani T, Faerman A et al (2002) Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene 21:6017–6031

    Article  CAS  PubMed  Google Scholar 

  10. Budanov AV, Karin M (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134:451–460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Peng M, Yin N, Li MO (2014) Sestrins function as guanine nucleotide dissociation inhibitors for Rag GTPases to control mTORC1 signaling. Cell 159:122–133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chantranupong L, Wolfson RL, Orozco JM et al (2014) The Sestrins interact with GATOR2 to negatively regulate the amino-acid-sensing pathway upstream of mTORC1. Cell Rep 9:1–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Budanov AV, Lee JH, Karin M (2010) Stressin’ Sestrins take an aging fight. EMBO Mol Med 2:388–400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kim SJ, Kim KM, Yang JH et al (2017) Sestrin2 protects against acetaminophen-induced liver injury. Chem Biol Interact 269:50–58

    Article  CAS  PubMed  Google Scholar 

  15. Shin BY, Jin SH, Cho IJ, Ki SH (2012) Nrf2-ARE pathway regulates induction of Sestrin-2 expression. Free Radic Biol Med 53:834–841

    Article  CAS  PubMed  Google Scholar 

  16. Bae SH, Sung SH, Oh SY et al (2013) Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab 17:73–84

    Article  CAS  PubMed  Google Scholar 

  17. Jegal KH, Ko HL, Park SM et al (2016) Eupatilin induces Sestrin2-dependent autophagy to prevent oxidative stress. Apoptosis 21:642–656

    Article  CAS  PubMed  Google Scholar 

  18. Saker M, Soulimane Mokhtari N, Merzouk SA et al (2008) Oxidant and antioxidant status in mothers and their newborns according to birthweight. Eur J Obstet Gynecol Reprod Biol 141:95–99

    Article  CAS  PubMed  Google Scholar 

  19. Gordijn SJ, Beune IM, Thilaganathan B et al (2016) Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 48:333–339

    Article  CAS  PubMed  Google Scholar 

  20. Guvendag Guven ES, Karcaaltincaba D, Kandemir O et al (2013) Cord blood oxidative stress markers correlate with umbilical artery pulsatility in fetal growth restriction. J Matern Fetal Neonatal Med 26:576–580

    Article  CAS  PubMed  Google Scholar 

  21. Granger JP, LaMarca BB, Cockrell K et al (2006) Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med 122:383–392

    PubMed  Google Scholar 

  22. Pardi G, Marconi AM, Cetin I (2002) Placental-fetal interrelationship in IUGR fetuses—a review. Placenta 23(Suppl A):S136–S141

    Article  PubMed  Google Scholar 

  23. Karowicz-Bilińska A, Suzin J, Sieroszewski P (2002) Evaluation of oxidative stress indices during treatment in pregnant women with intrauterine growth retardation. Med Sci Monit 8:CR211–CR216

    PubMed  Google Scholar 

  24. Saeedi V, Nourbakhsh M, Haghighi L et al (2021) Sestrin2 and Beclin1 levels in polycystic ovary syndrome. J Clin Lab Anal 35:e23957

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tayyar AT, Tayyar A, Kozali S et al (2019) Maternal serum sestrin 2 levels in preeclampsia and their relationship with the severity of the disease. Hypertens Pregnancy 38:13–19

    Article  CAS  PubMed  Google Scholar 

  26. Asadi N, Roozmeh S, Vafaei H et al (2022) Effectiveness of pentoxifylline in severe early-onset fetal growth restriction: a randomized double-blinded clinical trial. Taiwan J Obstet Gynecol 61:612–619

    Article  PubMed  Google Scholar 

  27. Yung HW, Alnæs-Katjavivi P, Jones CJ et al (2016) Placental endoplasmic reticulum stress in gestational diabetes: the potential for therapeutic intervention with chemical chaperones and antioxidants. Diabetologia 59:2240–2250

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Lee S, Shin J, Hong Y et al (2020) Sestrin2 alleviates palmitate-induced endoplasmic reticulum stress, apoptosis, and defective invasion of human trophoblast cells. Am J Reprod Immunol 83:e13222

    Article  CAS  PubMed  Google Scholar 

  29. Mitchell BM, Cook LG, Danchuk S, Puschett JB (2007) Uncoupled endothelial nitric oxide synthase and oxidative stress in a rat model of pregnancy-induced hypertension. Am J Hypertens 20:1297–1304

    Article  CAS  PubMed  Google Scholar 

  30. Potdar N, Singh R, Mistry V et al (2009) First-trimester increase in oxidative stress and risk of small-for-gestational-age fetus. BJOG 116:637–642

    Article  CAS  PubMed  Google Scholar 

  31. Ye J, Wang M, Xu Y et al (2017) Sestrins increase in patients with coronary artery disease and associate with the severity of coronary stenosis. Clin Chim Acta 472:51–57

    Article  CAS  PubMed  Google Scholar 

  32. Krause-Hauch M, Fedorova J, Zoungrana LI et al (2022) Targeting on Nrf2/Sesn2 signaling to rescue cardiac dysfunction during high-fat diet-induced obesity. Cells 11

Download references

Author information

Authors and Affiliations

  1. Department of Perinatology, Turkish Ministry of Health Ankara City Hospital, Ankara, Turkey

    Merve Ozturk Agaoglu, Zahid Agaoglu, Kadriye Yakut Yucel, Filiz Halıcı Ozturk & Turhan Caglar

Authors
  1. Merve Ozturk Agaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zahid Agaoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kadriye Yakut Yucel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filiz Halıcı Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Turhan Caglar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MO Agaoglu: project development, data collection, manuscript writing. Z Agaoglu: data collection, data analysis. KY Yucel: data collection. FH Ozturk: data analysis. T Caglar: project development, manuscript writing.

Corresponding author

Correspondence to Merve Ozturk Agaoglu.

Ethics declarations

Ethics approval and consent to participate

This study was performed in line with the principles of the Declaration of Helsinki. All procedures were approved by the Ethics committee of the Zekai Tahir Burak Research Hospital, Ankara, Turkey (Approval No.: 82/2019).

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Agaoglu, M.O., Agaoglu, Z., Yucel, K.Y. et al. Evaluation of maternal serum sestrin-2 levels in intrauterine growth restriction. Ir J Med Sci 192, 2259–2264 (2023). https://doi.org/10.1007/s11845-023-03329-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-023-03329-2

Keywords

Search

Navigation